

Special Issue

Epigenetic Mechanisms of Hematologic Malignancies

Message from the Guest Editor

This Special Issue will focus on the role of epigenetic mechanisms in hematologic malignancies and anti-cancer therapeutics that target aberrant epigenetic mechanisms in these cancers. We welcome high-quality manuscripts (reviews, research, and technology tool articles) with a focus on the following areas:

- Epigenetic mechanisms that drive or contribute to hematologic malignancies;
- Novel epigenetic targets in hematological malignancies;
- Development or use of targeted epigenetic therapies for hematologic malignancy;
- Methods for identifying aberrant epigenetic mechanisms in hematological malignancies.

Guest Editor

Dr. Richard L. Bennett

Division of Hematology and Oncology, Department of Medicine,
University of Florida, Gainesville, FL, USA

Deadline for manuscript submissions

closed (31 March 2025)



Epigenomes

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 4.4
Indexed in PubMed



mdpi.com/si/213135

Epigenomes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
epigenomes@mdpi.com

[mdpi.com/journal/
epigenomes](https://mdpi.com/journal/epigenomes)





Epigenomes

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 4.4
Indexed in PubMed



[mdpi.com/journal/
epigenomes](https://mdpi.com/journal/epigenomes)



About the Journal

Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

Epigenomes (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Editor-in-Chief

Prof. Dr. Ernesto Guccione

Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, NY 10029, USA

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, PubAg, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Biochemistry, Genetics and Molecular Biology (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).